GO:0008514 organic anion transmembrane transporter activity: Mechanism, Genes and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0008514 organic anion transmembrane transporter activity describes the molecular function of proteins that move organic anions across biological membranes.
• Key transporter families include OAT1 (SLC22A6), OAT3 (SLC22A8), ASBT (SLC10A2), PGT (SLCO2A1), and OATP transporters, which mediate renal, hepatic, and intestinal transport of endogenous and xenobiotic anions.
• Structural determinants such as transmembrane domain 1 and 12 of hOAT1 are critical for substrate recognition, stability, and maturation.
• Organic anion transporters are central to drug-drug interactions, prostaglandin reuptake, bile salt homeostasis, and CFTR activation.
• Dysregulation of organic anion transport is linked to metabolic disorders, cholestasis, and altered drug pharmacokinetics.
• CRISPR-based knockout, point mutation, and knock-in models enable causal dissection of transporter function in human cell lines and organoids.
Description
Organic anion transmembrane transporter activity (GO:0008514) is a molecular function that enables the directed movement of organic anions across cell membranes. Organic anions include a wide range of endogenous metabolites such as bile salts, prostaglandins, cyclic nucleotides, and hormones, as well as xenobiotics including drugs and their conjugates. This activity is essential for renal excretion, hepatic clearance, intestinal absorption, and cellular signaling. The transporters mediating this activity belong to the solute carrier (SLC) superfamily, notably the OAT (SLC22), OATP (SLCO), and ASBT (SLC10) families. Their functional characterization has revealed critical roles in pharmacokinetics, drug-drug interactions, and disease pathophysiology. For researchers, GO:0008514 provides a unified functional annotation for genes and proteins that share the ability to translocate organic anions, enabling comparative studies across tissues and species. Understanding the molecular basis of organic anion transport is essential for predicting drug disposition, designing transporter-targeted therapeutics, and modeling diseases such as cholestasis and hyperprostaglandinism. This article synthesizes authoritative QuickGO annotations and verified PubMed literature to provide a research-grade overview of GO:0008514, its mechanisms, key genes, and experimental approaches.
organic anion transmembrane transporter activity At A Glance
| GO ID | GO:0008514 |
|---|---|
| GO term | organic anion transmembrane transporter activity |
| Ontology | Molecular function |
| Synonym | None listed in QuickGO |
| Major function | Translocation of organic anions across biological membranes |
| Representative genes | SLC22A6 (OAT1), SLC22A8 (OAT3), SLC10A2 (ASBT), SLCO2A1 (PGT), SLCO1B1 (OATP1B1) |
| Substrates | Bile salts, prostaglandins, cyclic nucleotides, conjugated drugs, hormones |
| Tissue distribution | Kidney, liver, intestine, brain, placenta |
| Related diseases | Cholestasis, drug-induced toxicity, hyperprostaglandinism, metabolic disorders |
What Is GO:0008514?
GO:0008514 organic anion transmembrane transporter activity is defined as the molecular function that enables the transfer of organic anions from one side of a membrane to the other. Organic anions are negatively charged molecules containing carbon, such as bile acids, prostaglandins, and conjugated drugs. This activity is typically mediated by integral membrane proteins that undergo conformational changes to shuttle substrates across lipid bilayers. The term is classified under molecular function in the Gene Ontology and is distinct from channel activity or primary active transport, as it often involves facilitated diffusion or secondary active transport.
Why Is organic anion transmembrane transporter activity Important in Cell Biology?
Organic anion transmembrane transporter activity is critical for maintaining physiological homeostasis and determining the pharmacokinetics of numerous drugs. These transporters regulate the cellular uptake and efflux of endogenous signaling molecules such as prostaglandins and bile acids, thereby influencing inflammation, digestion, and energy metabolism. In the kidney and liver, they mediate the excretion of metabolic waste and xenobiotics, and their dysfunction can lead to drug accumulation and toxicity. Moreover, genetic variants in organic anion transporters are associated with interindividual variability in drug response and disease susceptibility. Thus, GO:0008514 is a key functional node for pharmacology, toxicology, and metabolic research.
• Mediates renal and hepatic clearance of drugs and metabolites, affecting drug half-life and toxicity.
• Regulates bile salt homeostasis and enterohepatic circulation, with implications for cholestasis.
• Controls prostaglandin reuptake, influencing inflammation and pain signaling.
• Determines the cellular uptake of antiviral, anticancer, and antihypertensive drugs.
• Genetic polymorphisms in OAT and OATP genes alter drug disposition and disease risk.
• Plays a role in CFTR activation via ASBT-mediated bile salt absorption.
• Contributes to the transport of thyroid hormone metabolites such as TRIAC.
• Serves as a target for natural product-drug interactions.
• Essential for nutrient and hormone transport across the blood-brain barrier and placenta.
• Provides a functional annotation for comparative genomics and transporter evolution studies.
Molecular Mechanism of organic anion transmembrane transporter activity
Substrate Recognition and Binding
In simple terms: The transporter first grabs the organic anion molecule.
Organic anion transporters recognize substrates through specific amino acid residues in their transmembrane domains. For hOAT1, critical residues in transmembrane domain 1 (TM1) are essential for substrate binding and transport activity. Mutational analysis has shown that charged and polar residues within TM1 interact with the anionic moiety of substrates, determining specificity for compounds such as p-aminohippurate and prostaglandins. Similarly, the prostaglandin transporter PGT (SLCO2A1) uses a conserved binding pocket to recognize prostaglandin E2. These interactions are often pH-dependent, as protonation of key residues can alter substrate affinity.
Conformational Changes and Translocation
In simple terms: The transporter changes shape to move the molecule across the membrane.
After substrate binding, organic anion transporters undergo conformational changes that expose the substrate to the opposite side of the membrane. This process is thought to follow an alternating access mechanism, where the transporter switches between outward-facing and inward-facing states. For hOAT1, transmembrane domain 12 (TM12) contributes to transporter stability and maturation efficiency, and mutations in this domain can impair translocation. The energy for transport can come from ion gradients (e.g., sodium or proton gradients) or from facilitated diffusion down the electrochemical gradient.
Substrate Release and Recycling
In simple terms: The transporter releases the molecule and resets for another round.
Following translocation, the organic anion is released into the cytoplasm or extracellular space, and the transporter returns to its initial conformation. This cycle is regulated by intracellular signaling and protein-protein interactions. For example, ASBT-mediated bile salt uptake can activate CFTR, linking transport activity to ion channel regulation. The recycling of transporters between the plasma membrane and intracellular vesicles also modulates overall transport capacity.
Regulation by Cofactors and Post-translational Modifications
In simple terms: Other molecules and chemical tags can tweak how well the transporter works.
Organic anion transporter activity can be modulated by cofactors such as sodium ions, protons, and chloride ions. Post-translational modifications, including phosphorylation and glycosylation, affect transporter trafficking and stability. For instance, hOAT1 maturation efficiency is influenced by its glycosylation state, and mutations in TM12 alter its stability. Additionally, natural products can inhibit or activate these transporters, leading to clinically relevant drug interactions.
Substrate Specificity and Multispecificity
In simple terms: Some transporters can carry many different molecules, while others are picky.
Many organic anion transporters are multispecific, handling a broad range of substrates. For example, OAT1 and OAT3 transport endogenous metabolites (e.g., urate, prostaglandins) and drugs (e.g., diuretics, antivirals). In contrast, ASBT is more selective for bile salts. The molecular basis for multispecificity lies in flexible binding pockets that accommodate diverse anionic structures. This property is exploited in drug design but also underlies drug-drug interactions.
Key Genes Involved in GO:0008514 organic anion transmembrane transporter activity
The following genes encode proteins that exhibit organic anion transmembrane transporter activity (GO:0008514) and have been functionally characterized in the literature.
| Gene | Major Role | Research Relevance |
|---|---|---|
| SLC22A6 (OAT1) | Renal organic anion transporter; mediates uptake of p-aminohippurate, antivirals, diuretics | Model for drug-drug interactions and nephrotoxicity |
| SLC22A8 (OAT3) | Renal and hepatic transporter for urate, prostaglandins, and drugs | Target for hyperuricemia and drug disposition studies |
| SLC10A2 (ASBT) | Intestinal bile salt transporter; coupled to CFTR activation | Cholestasis and bile acid diarrhea models |
| SLCO2A1 (PGT) | Prostaglandin reuptake transporter; regulates PGE2 signaling | Inflammation and cancer research |
| SLCO1B1 (OATP1B1) | Hepatic uptake of statins, bilirubin, and hormones | Statin-induced myopathy and hyperbilirubinemia |
| SLCO1B3 (OATP1B3) | Hepatic transporter for bile salts and drugs | Drug-induced liver injury studies |
| SLC22A11 (OAT4) | Placental and renal transporter for urate and drugs | Preeclampsia and gout research |
| SLC22A12 (URAT1) | Renal urate reabsorption transporter | Gout and hyperuricemia models |
| SLC22A7 (OAT2) | Hepatic transporter for cyclic nucleotides and drugs | Liver metabolism studies |
| SLC22A13 (OAT10) | Renal and intestinal transporter for nicotinate and urate | Niacin metabolism research |
| SLCO1A2 (OATP1A2) | Brain and renal transporter for drugs and hormones | Blood-brain barrier studies |
| SLCO4C1 (OATP4C1) | Renal transporter for uremic toxins and drugs | Chronic kidney disease research |
| SLC17A1 (NPT1) | Renal organic anion transporter for urate and drugs | Gout and drug excretion studies |
| SLC22A2 (OCT2) | Organic cation transporter; can transport some anions | Drug interaction studies |
| ABCC2 (MRP2) | ATP-dependent organic anion efflux pump | Biliary excretion and cholestasis |
| ABCG2 (BCRP) | ATP-dependent efflux transporter for organic anions | Multidrug resistance research |
How Is organic anion transmembrane transporter activity Regulated?
Organic anion transmembrane transporter activity is regulated at multiple levels. Transcriptional regulation by nuclear receptors such as FXR, PXR, and CAR controls the expression of OAT and OATP genes in response to bile acids and xenobiotics. Post-transcriptional mechanisms include phosphorylation, ubiquitination, and glycosylation, which affect transporter trafficking and stability. For example, hOAT1 maturation efficiency is determined by its transmembrane domain 12, and mutations in this region alter protein stability. Additionally, substrate availability and ion gradients modulate transport rates. Hormonal signals, such as prostaglandins, can feedback on transporter expression. These regulatory layers ensure adaptive responses to metabolic and pharmacological challenges.
organic anion transmembrane transporter activity and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| SLC22A6 (OAT1) | Drug-induced nephrotoxicity | Knockout HEK293 cells for transport assays |
| SLCO1B1 (OATP1B1) | Statin-induced myopathy | Knock-in mice expressing human variant |
| SLC10A2 (ASBT) | Bile acid diarrhea and cholestasis | Intestinal organoids with ASBT knockout |
| SLCO2A1 (PGT) | Chronic inflammation and cancer | Overexpression in cancer cell lines |
| SLC22A12 (URAT1) | Gout and hyperuricemia | Point-mutation knock-in mice |
Organic Anion Transporters in Drug-Induced Toxicity and Pharmacokinetics
Altered organic anion transport activity can lead to drug accumulation and toxicity. For instance, inhibition of OAT1 and OAT3 by co-administered drugs increases plasma levels of antivirals and diuretics, causing nephrotoxicity. Genetic variants in SLCO1B1 reduce hepatic uptake of statins, increasing myopathy risk. These examples highlight the clinical importance of GO:0008514 in personalized medicine and drug safety.
Cholestasis and Bile Salt Transport Disorders
ASBT (SLC10A2) mediates intestinal bile salt absorption, and its dysfunction contributes to bile acid diarrhea and cholestasis. ASBT activation can also stimulate CFTR, linking bile salt transport to chloride secretion. Mutations in bile salt transporters cause progressive familial intrahepatic cholestasis, underscoring the role of organic anion transport in liver disease.
Prostaglandin Reuptake and Inflammation
The prostaglandin transporter PGT (SLCO2A1) mediates reuptake of prostaglandin E2, terminating its signaling. Dysregulated PGT activity is associated with chronic inflammation and cancer progression. Targeting PGT may offer therapeutic opportunities for inflammatory diseases.
Metabolic Disorders and Urate Transport
Organic anion transporters such as URAT1 (SLC22A12) and OAT4 (SLC22A11) regulate urate reabsorption in the kidney. Hyperuricemia and gout are linked to gain-of-function variants in URAT1 or loss-of-function in OAT transporters. These findings position GO:0008514 as a key pathway in metabolic disease.
From organic anion transmembrane transporter activity-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of OAT1 affect drug uptake? | SLC22A6 knockout HEK293 or HeLa cells |
| How does a point mutation in TM1 alter substrate specificity? | Point-mutation knock-in of SLC22A6 in cell lines |
| Can ASBT-mediated bile salt transport activate CFTR? | ASBT knockout intestinal epithelial cells |
| What is the role of PGT in prostaglandin signaling? | SLCO2A1 overexpression and knockout cancer cells |
| Does a disease-associated variant in SLCO1B1 alter statin transport? | Knock-in mice carrying human SLCO1B1 variant |
| How does TM12 mutation affect OAT1 stability? | Tagged knock-in of mutant SLC22A6 for degradation studies |
How to Study the organic anion transmembrane transporter activity Process
| Method | What It Measures | Typical Application |
|---|---|---|
| Radiolabeled uptake assay | Transport rate and kinetics | Characterizing OAT1/OAT3 substrates |
| Fluorescence-based transport assay | Real-time transport activity | High-throughput drug interaction screening |
| Patch-clamp electrophysiology | Electrogenic transport currents | ASBT-CFTR coupling studies |
| Proteomics | Protein interactions and modifications | Identifying OAT1 regulatory partners |
| CRISPR knockout screen | Genes affecting transport activity | Discovering novel regulators |
| Site-directed mutagenesis | Residue-specific function | Mapping TM1 and TM12 determinants |
| Immunofluorescence imaging | Subcellular localization | Trafficking and stability studies |
| RNA-seq | Transcriptional changes | Regulation by nuclear receptors |
Transport Assays with Radiolabeled Substrates
Radiolabeled organic anions such as [3H]p-aminohippurate or [3H]prostaglandin E2 are used to measure uptake in cells expressing specific transporters. These assays quantify transport kinetics (Km, Vmax) and inhibition by drugs. They are essential for characterizing GO:0008514 activity.
Electrophysiology and Fluorescence-Based Transport Assays
For electrogenic transporters, patch-clamp or voltage-sensitive dyes can measure transport currents. Fluorescent substrates (e.g., fluorescein-methotrexate) enable high-throughput screening of transporter activity and inhibition. These methods provide real-time readouts of organic anion transport.
Proteomics and Interaction Studies
Mass spectrometry-based proteomics can identify interacting partners and post-translational modifications of organic anion transporters. Co-immunoprecipitation and proximity ligation assays reveal protein complexes that regulate transporter trafficking. These approaches link GO:0008514 to cellular signaling networks.
CRISPR Screening and Functional Genomics
Genome-wide CRISPR knockout screens can identify genes that modulate organic anion transport activity. For example, a screen for regulators of OAT1-mediated uptake can uncover novel trafficking factors. Such screens are powerful for discovering therapeutic targets and understanding transporter regulation.
How CRISPR Can Be Used to Study GO:0008514 organic anion transmembrane transporter activity
Knockout
CRISPR knockout of SLC22A6, SLC22A8, or SLCO2A1 in human cell lines abolishes organic anion transport activity, providing a clean background for studying specific transporters. Knockout models are used to confirm substrate specificity and to assess compensatory mechanisms.
Point Mutation
CRISPR-mediated point mutations can mimic naturally occurring variants or disrupt critical residues in transmembrane domains. For example, mutating TM1 residues in SLC22A6 alters substrate recognition. Point-mutation models help dissect structure-function relationships of GO:0008514.
Knock-in
Knock-in of tagged or humanized transporter genes enables tracking of protein localization and stability. Tagged knock-in of SLC22A6 allows monitoring of maturation efficiency and trafficking. Humanized knock-in mice carrying SLCO1B1 variants are used to study statin pharmacokinetics.
Overexpression
Overexpression of organic anion transporters in HEK293 or HeLa cells increases transport capacity and facilitates kinetic studies. Overexpression models are also used to screen for inhibitors and to study prostaglandin reuptake.
How EDITGENE Supports organic anion transmembrane transporter activity Research
Researchers studying organic anion transmembrane transporter activity-related genes often need to determine whether a candidate gene is causally involved in substrate transport, drug response, or disease phenotypes. EDITGENE provides comprehensive CRISPR-based services to generate precisely engineered cell models for functional validation of GO:0008514-associated genes.
Contact EDITGENE today to design your custom CRISPR model for organic anion transmembrane transporter activity research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| SLCO4A1 Knockout HEK293 Cell Line | EDJ-KQ8847 | Human | 28231 | Details Get a Quote |
| SLCO4A1 Knockout A-549 Cell Line | EDJ-KQ35158 | Human | 28231 | Details Get a Quote |
| SLCO4A1 Knockout HCT 116 Cell Line | EDJ-KQ35159 | Human | 28231 | Details Get a Quote |
| SLCO4A1 Knockout HeLa Cell Line | EDJ-KQ35160 | Human | 28231 | Details Get a Quote |
Displaying Records 1 To 4 Of 4 Records
Frequently Asked Questions About organic anion transmembrane transporter activity
What is GO:0008514 organic anion transmembrane transporter activity?
It is a molecular function term describing proteins that move organic anions across cell membranes, as defined by the Gene Ontology.
What genes are involved in organic anion transmembrane transporter activity?
Key genes include SLC22A6 (OAT1), SLC22A8 (OAT3), SLC10A2 (ASBT), SLCO2A1 (PGT), and SLCO1B1 (OATP1B1).
Which diseases are linked to organic anion transporters?
They are linked to drug-induced toxicity, cholestasis, hyperuricemia, and inflammatory disorders.
How can I study organic anion transport in the lab?
Common methods include radiolabeled uptake assays, fluorescence-based transport assays, and CRISPR knockout models.
What is the role of OAT1 in drug transport?
OAT1 (SLC22A6) mediates renal uptake of drugs and metabolites, and its inhibition can cause drug accumulation.
How does ASBT regulate CFTR?
ASBT-mediated bile salt absorption can activate CFTR, linking bile acid transport to chloride secretion.
What is the function of PGT (SLCO2A1)?
PGT mediates prostaglandin E2 reuptake, terminating its signaling and regulating inflammation.
Can CRISPR be used to study organic anion transporters?
Yes, CRISPR knockout, point mutation, and knock-in models are widely used to dissect transporter function.
What are the substrates of organic anion transporters?
Substrates include bile salts, prostaglandins, cyclic nucleotides, urate, and conjugated drugs.
Where are organic anion transporters expressed?
They are expressed in kidney, liver, intestine, brain, and placenta.
Conclusion
GO:0008514 organic anion transmembrane transporter activity is a fundamental molecular function that governs the movement of diverse organic anions across cellular membranes. Its roles in drug disposition, bile acid homeostasis, prostaglandin signaling, and urate handling make it a critical node in pharmacology, toxicology, and metabolic disease research. Advances in CRISPR-based models and functional assays continue to unravel the structure-function relationships and regulatory networks of these transporters. Understanding GO:0008514 will aid in predicting drug interactions, designing targeted therapies, and modeling human diseases.
References
- 1. Bi Y et al.. 2023. Transporter-mediated Natural Product-Drug Interactions.. Planta Med 89(2):119-133 PMID: 35304735
- 3. Bijvelds MJ et al.. 2005. Activation of CFTR by ASBT-mediated bile salt absorption.. Am J Physiol Gastrointest Liver Physiol 289(5):G870-9 PMID: 16037545
- 4. Zhu Z et al.. 2025. Molecular basis of prostaglandin E(2) reuptake by organic anion transporter PGT.. Nat Commun 17(1):315 PMID: 41326388
- 5. Hong M et al.. 2004. Critical amino acid residues in transmembrane domain 1 of the human organic anion transporter hOAT1.. J Biol Chem 279(30):31478-82 PMID: 15145940
- 6. Becker PC et al.. 2024. Identification of Human TRIAC Transmembrane Transporters.. Thyroid 34(7):920-930 PMID: 38801167
- 7. Hong M et al.. 2010. Putative transmembrane domain 12 of the human organic anion transporter hOAT1 determines transporter stability and maturation efficiency.. J Pharmacol Exp Ther 332(2):650-8 PMID: 19892921
- 8. Burckhardt G et al.. 2002. Molecular characterization of the renal organic anion transporter 1.. Cell Biochem Biophys 36(2-3):169-74 PMID: 12139402
